Antibody Capsid Binding for rAAV Biodistribution Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant adeno-associated virus (rAAV) gene therapy methods face challenges in restricting biodistribution to target tissues and organs, leading to systemic toxicity and immune responses due to incomplete localization and transduction in non-target tissues, such as the liver, which can result in adverse effects like thrombocytopenia and liver damage.
Innovation Solution
The method involves adjunctive systemic administration of antibodies or antigen-binding fragments capable of neutralizing non-systemically administered rAAV, specifically targeting capsid proteins of various AAV serotypes to restrict biodistribution and reduce systemic toxicity and immune responses by neutralizing rAAV in non-target organs and tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If rAAV is administered locally to target tissue, then transduction efficiency at target site is improved, but complete localization is not achieved and systemic circulation occurs leading to transduction in distal tissues
Solution Approach 1:
The patent introduces an intermediary substance (capsid-binding agent) that specifically binds to the rAAV capsid in the bloodstream, preventing it from transducing non-target tissues. This mediator selectively removes circulating rAAV without affecting the rAAV already delivered to the target tissue, thereby resolving the contradiction between achieving complete localization and preventing systemic toxicity
Solution Approach 2:
The patent extracts or removes the harmful circulating rAAV from the system by introducing capsid-binding agents that bind to and sequester the virus in the bloodstream. This extraction approach eliminates the problematic systemic circulation component while preserving the beneficial local transduction at the target site
2Productivity
If high doses of rAAV are administered to achieve therapeutic effect, then gene delivery efficacy is improved, but acute toxicity including thrombocytopenia and liver damage occurs
Solution Approach 1:
The capsid-binding agent acts as a mediator that selectively neutralizes excess rAAV in the bloodstream, allowing high doses to be administered for therapeutic efficacy while preventing the acute toxicities associated with high systemic circulation levels. The mediator clears circulating virus without interfering with therapeutic transduction at the target site
Solution Approach 2:
The patent applies partial neutralization by introducing capsid-binding agents that remove a portion of the administered rAAV from circulation. This partial action allows sufficient rAAV to reach the target tissue for therapeutic effect while eliminating the excess that would cause acute toxicity, effectively managing the dose-response relationship
3Area of stationary object
If rAAV transduces non-target tissues such as liver, then biodistribution coverage is improved, but immune responses and systemic inflammation are activated
Solution Approach 1:
The patent extracts rAAV from the bloodstream before it can transduce non-target tissues like the liver. By removing circulating rAAV through capsid-binding agents, the system achieves selective biodistribution restriction, preventing immune activation in non-target organs while maintaining therapeutic transduction at the intended site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively limits rAAV transduction in non-target tissues, reducing systemic toxicity and immune responses, thereby enhancing the safety and efficacy of rAAV gene therapy by ensuring targeted delivery and minimizing adverse effects.
Implementation Method 1
a composition comprising antibodies or antigen-binding fragments thereof that are capable of neutralizing the non-systemically administered rAAV
Data Source
AI summary
The present disclosure relates to an improved method of treating a patient with a recombinant adeno-associated virus (rAAV) by adjunctively administering to the patient via systemic administration a composition comprising at least one antibody or antigen-binding fragments thereof that is capable of neutralizing the non-systemically administered rAAV. The present disclosure further provides kits for the combination therapy.